BioVaxys Appoints New CFO and Announces Board Changes
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) has announced the appointment of Dasha Enenko as its new Chief Financial Officer (CFO), effective immediately. In addition to this, Craig Loverock, the outgoing CFO, has been appointed to the Board of Directors.
Enenko’s Accounting Experience
Enenko is a Chartered Professional Accountant with over 12 years of accounting experience. She has worked with private, public, and non-for-profit entities in a broad range of industries, including e-commerce, technology, manufacturing, food and beverages, and real estate. Her responsibilities have included the preparation and filling of interim and annual financial statements for publicly traded companies, working with auditors to ensure successful completeness of audit and review engagements, and helping clients with prospectus preparations.
Enenko’s Role in BioVaxys
Enenko will be responsible for the financial management of BioVaxys, including accounting, financial reporting, budgeting, and forecasting. She will play a key role in BioVaxys’ strategic planning, financial analysis, and overall management of the company’s finances.
Loverock’s Appointment to the Board of Directors
Craig Loverock, the outgoing CFO of BioVaxys, has been appointed to the Board of Directors. Loverock is a financial expert and will chair the audit and other relevant board committees. BioVaxys thanks Loverock for his outstanding work as CFO during his tenure.
Loverock’s New Responsibilities
Loverock will now have the added responsibility of overseeing BioVaxys’ financial affairs from a board level. As the Chair of the audit committee, he will be responsible for ensuring that the company’s financial reporting is accurate and transparent. Loverock’s expertise in finance and accounting will be an asset to the Board of Directors.
David Wang’s Resignation from the Board of Directors
David Wang has resigned from BioVaxys’ Board of Directors. Wang is returning to China to reside full-time and will not be able to commit adequate time to serve as a director of the company. Wang has been appointed as an Advisor to BioVaxys to assist the company with business development in China. This includes identifying potential licensing, sales, and M&A opportunities with Chinese pharmaceutical companies.
Passin’s Statement on the Changes
James Passin, BioVaxys CEO, stated, “We are delighted to onboard Dasha Enenko as CFO as we continue the work of advancing our product portfolio. We thank Craig for his outstanding work as CFO during his tenure and welcome him to the Board of Directors. We are excited to continue to work with former Director David Wang on opportunities in China.”
The appointment of Dasha Enenko as CFO and Craig Loverock’s appointment to the Board of Directors are significant changes for BioVaxys. Enenko’s financial experience will be an asset to the company, and Loverock’s expertise will help to ensure accurate and transparent financial reporting. David Wang’s resignation from the Board of Directors is a loss for the company, but his new role as an Advisor to BioVaxys will continue to strengthen the company’s business development in China.